Pharsight

Shorla patents expiration

1. Jylamvo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771701 SHORLA Methotrexate formulation
Oct, 2034

(10 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 29 November, 2022

Treatment: Treatment of adults with acute lymphoblastic leukemia with an oral solution of methotrexate; Treatment of adults with mycosis fungoides with an oral solution of methotrexate; Treatment of adults with ...

Dosage: SOLUTION;ORAL

More Information on Dosage

JYLAMVO family patents

Family Patents